Dexamethasone is an anti-inflammatory that in excess, or after prolonged exposition, may alter the glucose and lipid homeostasis. Omega-3 fatty acids, present in fish oil (FO), can be used as potential modulators of intermediary glucose and lipid metabolism.
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INTRODUCTION
Dexamethasone (Dex) is an effective synthetic glucocorticoid (GC) to treat numerous immune-inflammatory related diseases like rheumatoid arthritis, asthma, allergy, autoimmune diseases, and organ transplant rejection. However, GC treatment can be associated with many metabolic disorders, such as hyperlipidemia, hepatosteatosis, hyperglycemia, insulin resistance and hypertension (Andrew et al. 2002; Czock et al. 2005; Rafacho et al. 2008) .
Studies in rats treated with 1.0 mg.kg B.W.
-1 for 5 days have shown an increase in concentrations of plasma triacylglycerol (TAG) and increased visceral adiposity (Rafacho et al. 2008; Nunes et al. 2013; Motta et al. 2014) . These alterations in lipid profile also can be observed in other studies in rats treated with higher doses of Dex (e.g. 5 mg.kg B.W.
-1 for 7 days) (Nicastro et al. 2012; Zanchi et al. 2012 ) and lower doses for prolonged time (e.g. 0.25 mg.kg B.W.
-1 for 28 days) (Chimin et al. 2014 ).
In human patients treated with glucocorticoids for asthma, cardiac and renal transplants and rheumatoid arthritis it has been shown elevations in total cholesterol (TC), triglycerides (TG) and low-density lipoprotein (LDL), and variable changes in high-density lipoprotein (HDL) (Sholter et al. 2000) .
Dyslipidemia associated with GCs may result from direct and/or indirect action GC on lipolysis in adipose tissue, the production and turnover of free fatty acids (FFA), very low density lipoprotein synthesis (VLDL) and accumulation of fatty acids (FA) in the liver (Arnaldi et al. 2010) . Additionally, GC use can disturb glucose homeostasis by inducing insulin resistance through modifications in the phosphorylation status of several proteins regarding insulin response (e.g. Akt/PKB and Insulin Receptor
Substrate-1 (IRS-1)) (Motta et al. 2014 ).
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The metabolic changes caused by treatment with Dex can be a limiting factor to its long-term use (Sholter et al. 2000; Arnaldi et al. 2010) . Thus, strategies must be investigated in order to reduce the side effects of Dex. Some data suggest that omega-3 (n-3) polyunsaturated fatty acids (PUFAs), especially eicosapentaenoic acid (EPA-20:5n-3) and docosahexaenoic acid (DHA-22:6n-3), present in fish oil (FO), are associated with alterations in the lipid homeostasis, resulting in the reduction of risk factors for various diseases such as dyslipidemia, cardiovascular disease, type 2 diabetes mellitus (DM2) and metabolic syndrome (Yang et al. 2011; Hirabara et al. 2012 ).
The n-3 fatty acids, as EPA and DHA, alters metabolic pathways and modulates gene expression resulting in improved insulin sensitivity, attenuated dyslipidemia and hepatic TAG content. It has been suggest that these results provide a rational basis for the use of EPA and DHA as an alternative treatment for patients with metabolic syndrome (Castro et al. 2015) . It is known that n-3 PUFA incorporation in phospholipid membranes is linked to modulation of tissues' insulin response (Calder 2012), a fact that can be related to plasma triglyceride content reduction (Yamazaki et al. 2011; Alexander-Aguilera et al. 2011) . Furthermore, the n-3 PUFAs can modulate the activity of peroxisome proliferator activated receptors (PPARs), transcriptions factors that control the expression of genes involved in lipid and glucose metabolism (Ferreira et al. 2013 ).
Considering the biological effects of FO consumption on lipid and glucose metabolism in other models, it is possible to speculate a potential therapeutic effect of FO supplementation on the adverse metabolic effects caused by Dex. Therefore, in this study, we investigated the effects of supplementation with FO (1g.kg B.W. Figure 1 ).
Metabolic measurements
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Body weight, food intake and water were monitored daily from one day prior to the start of supplementation until the day of euthanasia. On the eighth day, after fasting for 12-14h, the rats had the blood collected from the tail to measure blood glucose levels with a glucometer (Accu-Check1 Performa; Roche Diagnostics GmbH, Mannhein, Germany)
and it was also collected in a tube previously washed with saline, containing heparin as anticoagulant (Hemofol   ®   ) . The plasma, obtained after blood centrifugation, was used to measure the TAG, total cholesterol (TC) and HDL-C by enzymatic colorimetric methods according to manufacturer's instructions (Biotécnica ® , Varginha, MG, Brazil) using a spectrophotometer (Abell et al. 1952; Burstein et al. 1970; Bucolo and David 1973) . The fraction of non-HDL-C was obtained by the following calculation: TC -
On the sixteenth day, after 12-14h fasting, blood glucose levels were measured with a glucometer. In the next day, the fasted rats were euthanized (exposure to CO 2 followed by decapitation), the trunk blood was collected in tubes, previously washed with saline, containing heparin as anticoagulant (Hemofol ® ). The plasma obtained was used to measure the TAG, TC and HDL-C as previously described. Organs and tissues were carefully removed and weighed.
Another set of fasted (12-14 h) rats was used for the ipPTT experiments. Conscious rats had their blood collected and glycemia measured (time 0) similar to the procedure for the ipGTT analysis. A pre-warmed (36 ºC) 25% pyruvate solution was immediately administered (1.5 g.kg B.W.
-1 , i.p.), and blood samples were collected from the tail tip at 30, 60 and 120 min to measure the blood glucose levels. From these values we calculated the area under the curve (AUC) (Ferreira et al. 2012; Nagajyothi et al. 2013) .
Intraperitoneal insulin tolerance test (ipITT)
Distinct groups of fed rats were used for ipITT experiments. Conscious rats had their .
Hepatic triacylglycerol content
Liver fatty acids profile
The profile of fatty acids in liver was determined by High Performance Liquid Chromatrography (HPLC), according to Nishiyama-Naruke et al. (1997) . Fatty acids constituent of phospholipids, triacylglycerols, cholesterol esters, and free fatty acids were extracted using chloroform:methanol (2:1,v:v), adapting method described by Folch et al. (1957) . Lipid extracts were suspended in methanol and the pH adjusted to ≥12 with 5 mol.L -1 NaOH. The aqueous solution was acidified with hydrochloric acid (pH ≤3) and subjected to a new lipid extraction by hexane, followed by evaporation by N 2 gas at 37 ºC. Fatty acids were derivatized with 4-bromomethyl-7-coumarin and acetonitrile according Abushufa, Reed and Weinkove (1994) , and subsequently 
Western blot analysis
Immediately after the death of animals, the liver tissue fragments were removed and frozen in liquid nitrogen for later analysis. These fragments were homogenized in lysis solution at 4°C (Cell Signaling, MA, USA) in ultraturrax (IKA ® ) for 3 sets of 15 seconds each. Subsequently were centrifuged at 13.000 x g for 50 min at 4°C
(Eppendrof 5804R). The determination of the total protein concentration of the lysate was performed by the Bradford method (1976) according to the manufacturer's instructions (Bio-Rad, CA, USA). Aliquots of total protein (100 mg) were boiled at 100°C for 4 minutes in 25% of the volume of Laemmli buffer (1M sodium phosphate pH 7.0, 10% SDS, 10% β-mercaptoethanol, 50% glycerol, 0,1% bromophenol blue).
The samples were subjected to electrophoresis (Mini Protean II -Bio-Rad) in polyacrylamide gel (6.5-15%). After electrophoresis, proteins were transferred to nitrocellulose membrane (Santa Cruz Biotechnology) in presence of 20% methanol and 1% SDS at 120V constant voltage for 2 hours (Shapiro et al. 1967 Chemidoc MP system (BioRad, CA, USA) as described by the manufacturer. Band quantification was performed using the image processing and analysis software Chemidoc MP (BioRad, CA, USA).
Statistical analysis
All analyzes were performed using Graphpad prism v.5.01 (Graphpad Inc.; La Jolla, USA) software. The symmetry of the data was tested by Shapiro Wilk's test. Results are expressed as the mean ± standard error of the mean (SEM) when distribution was symmetric or as median and interquartile range when it was asymmetric. Analysis of variance (ANOVA) (one-way ANOVA) for unpaired groups followed by Tukey's posthoc test were utilized for multiple comparisons of parametric data or Kruskal-wallis followed by Dunn's post hoc when variables presented asymmetric distribution. When the text refers to "their respective control groups" for DEX and DFO groups, it means DEX vs. CTL and DFO vs. FO groups, respectively. The significance level adopted was p < 0.05.
RESULTS
Treatment with dexamethasone decreases the body weight, food intake and changes the mass of tissues and organs.
The initial body weight of the rats was similar in all groups. After the second day of treatment, there was a progressive reduction in the weight of the animals treated D r a f t 13 with Dex. There was a statistically significant reduction of food intake only between DEX and CTL groups, but in all groups the intake decreased during treatment (Table 1) .
The relative mass of the epididymal adipose tissue and liver were significantly higher in rats treated with Dex as compared to their respective control. In addition, the mass of retroperitoneal adipose tissue and the adrenal were significantly reduced by use of Dex (Table 1 ). The supplementation with fish oil did not change any of these parameters.
Treatment with fish oil attenuates the increase in plasma lipid concentrations in rats treated with Dex
The plasma concentrations of TAG, TC, HDL-C and non-HDL-C in the half and at the end of treatment with Dex and supplementation with FO are presented in Figure   2 . The rats treated with Dex showed increased plasma concentrations of triacylglycerol on the eighth day of the treatment (CTL: 77.1±4.8; FO: 96.6±7.5; DEX: 197.0±11.9; DFO: 182.6±10.4 mg.dL -1 ) and, as observed in Figure 2 , the supplementation with fish oil had no effect in this parameter. Figure 3B ).
Fish oil supplementation promotes incorporation of EPA and DHA in liver.
After 15 days of supplementation with fish oil, the incorporation of the fatty acids EPA and DHA in the liver was significantly increased, as shown in table 2. The proportion of saturated and other unsaturated fatty acids, however did not significantly change in the tissue.
Epididymal and Retroperitoneal fat lipolysis rate.
There was a significant increase in the basal glycerol release by the epididymal 
Treatment with fish oil did not alter the glucose homeostasis in rats treated with Dex
The fasting glucose levels were significantly increased in rats treated with Dex compared to their respective control in the half and at the end of the treatment, no effect of supplementation with fish oil was observed. On the eighth day of treatment, glucose tolerance and pyruvate tolerance tests showed a significant increase in the AUC of rats treated with Dex. The supplementation with FO had no effect in these parameters.
However, at the end of treatment the glucose tolerance test, pyruvate tolerance test and insulin tolerance test showed no significant difference between all groups ( Table 3 ).
Revealing that the Dex effects in glucose metabolism are time dependent.
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DISCUSSION
The main finding of the current study was the attenuation of dyslipidemia (e.g.
TAG, TC and non-HDL-C) caused by Dex treatment after 15 days of concomitant fish oil ingestion. Another important aspect, showed by this study, was that the effect of plasma TAG was not evident on the first measure (on the 8 th day of supplementation), but only after the second measure (on the 17 th day). Noteworthy, in this model, the Dex- 
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It is known that the liver is responsible for the clearance of plasma free fatty acids leading to the synthesis of new TAG molecules (Nguyen et al. 2008 ). In the liver, n-3 fatty acids seem to stimulate β-oxidation and decrease lipogenesis (Takahashi et al. 2002) . A review performed with studies in humans showed that the n-3 PUFAs, EPA and DHA, have shown to decrease fasting TG concentrations. This conclusion was based on studies that used EPA+DHA in the form of FO capsules at doses >2 g.day -1
and showed 25-35% reductions in TG concentrations (Musa-Veloso et al. 2010 ).
Other studies with n-3 PUFA supplementation in obesity animal models showed Furthermore, the dexamethasone treatment is commonly used to study changes in glucose homeostasis (Saad et al. 1993; Burén et al. 2008 ). The supplementation with fish oil for 15 days did not attenuate the changes in body weight and glycemic parameters caused by treatment with Dex. In rats supplemented with 4.9% fish oil in the diet for 4 weeks and treated with Dex (1 mg.kg B.W.
-1 ) for 5 days there was incorporation of PUFA n-3 in liver, but also in skeletal muscle and adipose tissue.
However, the fish oil did not affect the increase in blood glucose, insulin, and the plasma concentrations of non-esterified fatty acids (NEFA), caused by Dex treatment (Corporeau et al. 2006; Le Foll et al. 2007 ). Besides the production of similar data, compared to the present study, the parameters related to Dex treatment and fish oil supplementation are far distinct from the ones applied on the present study for a proper comparison.
The increase on blood glucose concentrations during the fasting state is also one of the effects caused by treatment with Dex. This may be associated with increased gluconeogenesis and/or hepatic glycogenolysis, as suggested by studies showing decreased hepatic glycogen content and higher glycaemia curves during the pyruvate tolerance test (Beaudry et al. 2013; Cummings et al. 2013; Rafacho et al. 2014 ).
Additionally, increased basal glucagon concentrations (Rafacho et al. 2014) in rats treated with Dex may contribute for such higher fasting glycaemia. In rats, it has been shown that glucocorticoids induce expression of key gluconeogenic enzymes and also phosphoenolpyruvate carboxylase (Jin et al. 2004) . Such increment may contribute to enhance endogenous glucose production, potentially increasing the fasting glucose.
Previous studies have shown that the treatment with Dex promotes reduction of glucose tolerance (Burén et al. 2008; Rafacho et al. 2008; Chimin et al. 2014) . However, in our model, glucose tolerance was decreased only after 8 days of Dex administration at 0.5mg.kg B.W.
-1 , returning to control levels after additional 7 days of treatment. Our study was not designed to investigate such unusual result and we are not aware of other studies regarding this subject. Future might investigate this interesting topic, as the reproduction of the same response was homogenous in three different sets of rats (data not show).
In conclusion, fish oil (1 g.kg B.W.
-1 ) ingestion caused a significant attenuation on increased plasma triacylglycerol and total cholesterol levels caused by Dex treatment, during 15 days (0.5 g.kg B.W.
-1 ). However, no effect of the supplementation was evidenced, on the development of the same changes, on the initial 8 days of treatment and supplementation. Such time dependent effect need to be considered in future studies. Furthermore, fish oil ingestion does not seem to modify Dex-induced changes on glucose homeostasis (e.g. in fasting glycaemia). Therefore, fish oil can be a potential nutritional strategy to attenuate the dyslipidemia caused by Dex administration.
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